Oncology

What Happens When Colorectal Cancer Screening Guidelines Expand?

New guidelines have lowered the recommended starting age for colorectal cancer screening. One expert says clinicians need to do more to increase screening access and compliance while ensuring no patient population is left behind.


Is the CAR T-Cell Revolution Here?

A tailor-made oncology treatment, CAR T-cell therapy promises to transform cancer care. But can its potential overcome its problems?


Could a Multi-Cancer Early Detection Blood Test Signal a Seismic Shift for Cancer Screening?

Galleri, a test developed by California-based healthcare company Grail, can detect dozens of types of cancer — most of which currently lack a recommended screening test — with a single blood sample. What could that mean for the way clinicians screen for and treat cancer?


That’s News

Could Your Oncology Software Get Hacked?

Just as in politics and the energy business, hacking hospital systems is on the rise — and it’s not just patient privacy that’s at risk. In April, a security breach of oncology and radiology system provider Elekta took the radiation systems of numerous...


Who Needs Chemotherapy? For Breast Cancer Patients, the RxPONDER Trial Refines the Answer

Initial results from the Southwest Oncology Group (SWOG) phase 3 RxPONDER trial demonstrate that postmenopausal women with a common form of breast cancer may be able to forego chemotherapy — and its potential adverse effects — in favor of standalone hormone therapy.


Prostate Cancer Care Forges into the Future

Ongoing research offers new promise for patients with metastasized, castration-resistant prostate cancer.


Common Procedure for Gastric Cancer Shows Promise for North American Patients

Endoscopic submucosal dissection was shown to be highly effective at removing superficial gastric tumors and is a viable option for patients around the globe.


Leukemia Drugs for Lung Cancer?

Two recently approved treatments show promise in a new study.


Reassessing Mandatory Mastectomy Recommendations

New guidelines on how to treat hereditary breast cancer could be a gamechanger.


That’s News

A New Combination Therapy for HER2-Positive Metastatic Breast Cancer

The recent FDA approval of the drug Tukysa (tucatinib) for use with the chemotherapeutic agents trastuzumab and capecitabine provides a new treatment option to certain adults with HER2-positive breast cancer.

The...